Hematology

Prostate Cancer

Questions discussed in this category

How do you approach ADT in patients with high-risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?

1 Answer available

How do you manage drug-drug interactions between oral anticoagulants and the ARSI agents such as apalutamide and enzalutamide?

1 Answer available

Papers discussed in this category

Blood advances, 2018-11-27

American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

Blood Adv,

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.

Lancet Oncol, 2015 Feb 19

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

European urology, 2022 Apr 22

High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.

Arteriosclerosis, thrombosis, and vascular biology, 2020 Sep 03

Lifestyle Moderates Genetic Risk of Venous Thromboembolism: The ARIC Study.

The Lancet. Oncology, 2010 Apr 13

Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.

Frontiers in cardiovascular medicine, 2022 Mar 16

Association of Gonadotropin-Releasing Hormone Therapies With Venous Thromboembolic Events in Patients With Prostate Cancer: A National Cohort Study.

Cancer, 2015 Jul 06

Prostate cancer, comorbidity, and the risk of venous thromboembolism: A cohort study of 44,035 Danish prostate cancer patients, 1995-2011.

Related Topics in Hematology